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Abstract
Over the past two decades, huge amounts of research were launched to understand the functions of sphingosine.
Many pathways were uncovered that convey the relative functions of biomacromolecules. In this review, we discuss
the recent advances of the role of the SphKs/S1P/S1PR1 axis in immunity and cancer. Finally, we investigate the
therapeutic potential of new drugs that target S1P signaling in cancer therapy.
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Background
Sphingosine was first described by J. L. in the 1880s, and
its structure was characterized as 2S,3R,4E-2-aminoocta-
dec-4-ene-1,3-diol [1]. In the last two decades, research
has illustrated the significant functions of sphingosine in
physiology, pathology, and the chemical or structural
biology of metabolism.
Sphingosine kinases (SphKs) are comprised of two
forms, SphK1 and SphK2, which are upstream of S1P.
They catalyze the phosphorylation of sphingosine to S1P,
regulating the amount of S1P [2]. The functions of these
two S1P metabolic enzymes are critical. Double-knockout
animals were embryonic lethal, due to the incomplete
maturation of the vascular system and brain, although
mice deficient in either SphK1 or SphK2 had no obvious
abnormalities [3]. The differences in SphKs existed at an
early stage. On a macro level, SphKs are activated by
numerous stimuli, including chemokines, intercellular ad-
hesion molecules, and pro-inflammatory cytokines [4, 5].
On a molecular level, SphK1-S225A, Calcium and Integrin-
binding protein 1, Elongation Factor 1A (eEF1a), and
hypoxia regulate the specific microenvironment of SphKs
[6–8]. Sphingosine, SphKs, and S1P regulation was more
complex in cell nuclei. Hait N. C. et al. reported that the
S1P produced by SphK2 inhibited histone deacetylases
(HDACs), which modulated the dynamic balance of histone
acetylation and influenced the epigenetic regulation of
specific target genes [9]. SphK2 inhibited cell growth and
promoted apoptosis [2]. In addition, the binding of S1P was
also required for the E3 ubiquitin ligase activity of
TRAF2, an essential mediator of the nuclear factor-κB
(NF-κB) pathway initiated by the major inflammatory
signaling molecule TNF-α [10–12]. S1P may promote
cancer progression via HDAC1/2 and NF-κB intracellular
targets [4, 9, 10]. SphK1 was reported to contribute to S1P
synthesis by a combination of epigenetic, transcriptional,
and posttranslational mechanisms [13]. Therefore, SphK1
may have a more positive effect on S1P than SphK2.
It was unclear whether a SphKs/S1P regulatory loop
existed in cells. Pappu R found that in an “S1P-less”
mouse model, SphK1 and SphK2 were also disrupted
in blood stem cells, vasculature, liver, and additional
tissues [14].
Sphingosine-1-phosphate (S1P) is a common, complex
molecule biosynthesized in our bodies. Its complicated
structure forms via several steps. Sphingolipid biosyn-
thesis is initiated in the endoplasmic reticulum (ER)
[15]. Sphingolipid and S1P maintain a dynamic balance
via a series of biosynthetic or recycling/degradation
pathways and are phosphorylated or dephosphorylated
by specific and nonspecific lipid phosphatases [2].
In the ER, sphingosine-1-phosphate phosphatase 1
(SPP1) and sphingosine-1-phosphate phosphatase 2
(SPP2), two sphingoid base-specific phosphatases, regu-
late S1P levels [16]. SPP1 gains access to extracellular
S1P via its import into the cell by an ATP-binding cas-
sette (ABC) transporter [17], similar to agonists which
activate SphK1 by inducing its recruitment to the
* Correspondence: shi.yinghong@zs-hospital.sh.cn
1Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital,
Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion of
Ministry of Education, 180 FengLin Road, Shanghai 200032, China
Full list of author information is available at the end of the article
© 2016 Jin et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Jin et al. World Journal of Surgical Oncology  (2016) 14:131 
DOI 10.1186/s12957-016-0884-7
plasma membrane and producing S1P by “inside-out sig-
naling” [18–21]. SPP2 influences branching morphogen-
esis during kidney development by influencing S1P levels
in the metanephric mesenchyme [16].
As discussed above, SphKs hold important guide roles
in this process. Degradation is also important to balance
the amount of S1P. S1P is degraded by the intracellular
protein S1P lyase. In this process, the sphingoid base is
cleaved at position C2,3, yielding hexadecenal and etha-
nolamine phosphate [22]. S1P lyase was upregulated in
response to ischemia, radiation, and chemical injury in
other tissues [2] and was also regulated by PDGF signaling
[23]. Similar to SphKs, S1P lyase also maintained a dy-
namic balance.
Interestingly, the S1P lyase level in the blood was
much lower than that in tissues, leading to higher S1P
levels in the blood and lower amounts in tissues. Eryth-
rocytes and platelets lack S1P lyase or S1P phosphatase
activity when they mature [14]. Hagen found that loss of
S1P lyase (SPL) resulted in high, cytotoxic S1P levels in
the neurons and vital organs [24]. This observation is
contradictory to early studies in SPL null mice, which
form pathological lesions in the lung, heart, urinary
tract, and bone due to lack of S1P [9, 25]. Upstream of
S1P, many molecules need further study.
The S1P receptors are regulated through distinct mech-
anisms. Transcriptional regulation of S1PR1 is controlled
by Krüppel-like factor 2 (KLF-2), and S1PR1 is exquisitely
sensitive because of ligand-induced internalization [26].
Although the S1P receptors emit signals in the presence
of S1P, they also signal without S1P due to the down-
stream signaling of G protein partners [27]. Recent studies
exposed an interesting phenomenon, in which Dynamin-2
was essential for S1PR1 internalization and promoted
egress from both the thymus and lymph nodes wherever
high S1P concentrations existed [28].
S1PR1 correlated with S1PR1-JAK/STAT3 signaling in
Treg cells [29]. Its specific role in immunity is discussed
below.
The role of the SphK/S1P/S1PR1 axis in immune
regulation
SphK1-generated S1P participates in many physiological
and pathological processes. S1P binds to five-cell surface
receptors, called S1PR1-5. S1PRs performed important
functions. S1PR1 is particularly distinctive. It plays an im-
portant role in the mature vascular system, pathological
angiogenesis, immune cell egress from tissue compart-
ments, hematopoietic, vascular and stem cell survival, cyto-
kine production, and so on [30–34]. An interesting study
noted that SphKs-S1P exist in the mitochondria, where the
balance of their amounts influences respiration [12].
Hematopoietic stem and progenitor cells (HSPCs/
HSC/HPC) express S1P receptors. Following different
S1P gradients, HSPCs emigrated from peripheral tissues
to the lymphatic system [35, 36]. Coincidentally, the
egress of B cell progenitors from the bone marrow (BM)
depended on S1P/S1PR1 interactions [37]. Furthermore,
S1PR1 was required for the steady-state trafficking of
HSPCs. Suppression of S1PR1 expression by genetic or
pharmacologic methods significantly impaired the mobi-
lization of HSPCs into the blood. CXCR4 blockade or
the S1PR1 agonist SEW2871 enhanced AMD3100-
mediated HSC mobilization [38]. In addition, the release
of S1P from mast cells and erythrocytes in the periph-
eral circulation was dependent on ATP-binding cassette
(ABC) transporters. This phenomenon was similar in
either physiological or pathological situations [21, 39].
Interestingly, Henrik Fyrst raised the critical view why,
with the help of S1P receptors for immune cell egress,
some specific functions of non-lymphoid immune cells
existed, perhaps by an as yet unknown feedback mechan-
ism from other cells that influence S1P-S1PR (especially
S1PR1) sensitivity [2].
Apart from the function for HSPCs, S1P and its re-
ceptors influence many organs through systemic and
localized chemotactic gradients [40, 41]. Studies investi-
gated the mechanisms underlying these phenomena. In
an inflamed lymphoid organ, type 1 interferons (IFNs)
increased the lymphocyte expression of the activation
antigen CD69, which bound S1PR1 and induced its in-
ternalization and degradation through the loss of CCR7
in newly generated effector T cells, where S1PR1 was
upregulated [42, 43]. In the spleen, the S1P-S1PR1 axis
changed cyclically, which allowed B cell migration in a
CXC-chemokine receptor 5 (CXCR5-dependent man-
ner toward CXC-chemokine ligand 13 (CXCL13), which
is produced by follicular DCs [44]. Faroudi, M ex-
plained that S1PR1 played a crucial role in the reverse
transmigration of lymphocytes by regulating the small
GTPase RAC and potent actin nucleation, which were
required for the reorganization of the actin cytoskel-
eton [45]. Allende, M. L. et al. [37], using B cell-specific
S1PR1 knockout (B-S1PR1KO) mice, found that S1PR1
provided a signal necessary for the efficient transfer of
newly generated immature B cells from the bone mar-
row to the blood.
Many viewpoints illustrate the phenomenon that lym-
phocytes internalize in the lymphoid organs is via the
CCL21–CCR7 axis [42, 46, 47]. Recent studies illustrated
an interesting phenomenon. Collagen expression was
negatively regulated by S1PR1 and S1PR3 in human
bone marrow-derived mesenchymal stem cells (hMSCs)
[48]. The new focus may well be on collagen. One study
found that S1PR1 and integrin ß4 (ITGB4) were essential
for hepatocyte growth factor (HGF)-mediated EC barrier
enhancement [49]. In brief, S1P and its receptors function
on the macro-environment and microenvironment in the
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body via an “inside-out signaling” mechanism [4]. These
cumulative findings proved that S1P is a major regulator
of innate and adaptive immunity. At the same time, more
questions arose, including whether S1P signaling contrib-
utes to inborn or acquired immune diseases, and its long-
term effects on thymic education and peripheral lymphoid
organ functions.
The role of the SphK/S1P/S1PR1 axis in
pathophysiology/pathogenesis
The SphKs/S1P/S1PRs axis regulates many physiological
processes, including pathogenesis or pathophysiology. S1P
and its receptors regulate allergic responses, lymphocyte
differentiation, endothelial barrier integrity and cytokine
and adhesion molecule expression, asthma, rheumatoid
arthritis, sepsis, and inflammatory bowel disease [13, 18,
50–53]. IgE receptors on mast cells upregulated SphK1
(and probably SphK2), leading to S1P production. S1P in
turn activated its own receptors in an autocrine and/or
paracrine manner, which promoted mast cell activation
and degranulation [54]. Inhalation of SphK inhibitors im-
proved disease severity in a mouse model of asthma [55].
Histamine released from mast cells stimulated SphK1 and
enhanced S1P production by both hematopoietic and
nonhematopoietic sources, which was crucial for the
clearance of histamine [33]. Camerer, E explained that S1P
continuously activated luminal endothelial S1PR1 to
maintain tight cell–cell junctions. Following the entry of
S1P into the subendothelial space via “leaky” endothelium,
dynamic S1PR1 signaling activated abluminal surface
S1PRs to close intercellular gaps [50]. Endothelial cell
S1PR1 maintained the homeostatic barrier property of the
vascular system, and the SphK1/S1P/S1PR1 axis was in-
volved in the restoration of normal vascular barrier integ-
rity during infection and inflammation [50, 56].
In response to TNF and other cytokines, SphK1 was
activated and translocated to the plasma membrane to
catalyze the production of S1P, which was then exported
out of the cell by specific transporters to activate its re-
ceptors in an autocrine manner. In addition, S1P acti-
vated the key inflammatory transcription factor nuclear
factor-κB (NF-κB), which was found to be independent
of S1PRs [57–59]. In sepsis, both TLR2 and TLR4 stimu-
lated and upregulated SphK1 and downstream factors
such as NF-κB. Therefore, deletion or inhibition of
SphK1 prevented sepsis in mouse models of LPS chal-
lenge or cecal ligation and puncture [51]. This paved the
way for the exploration of SphK1 inhibitors for the treat-
ment of sepsis in humans [11]. In the liver, fibrosis is the
common response to chronic liver injury, characterized
by excessive deposition of collagen and other compo-
nents of the extracellular matrix [60, 61]. As illustrated
above, S1P played a critical role in lymphocyte egress
from secondary lymphoid tissues and the thymus. Li C
established acute and/or chronic liver injury by carbon
tetrachloride injection or bile duct ligation (BDL) in
mice, and found that S1P levels in liver tissue and serum
were significantly increased [62]. S1P levels in the hu-
man fibrotic liver were increased through up-regulation
of sphingosine kinase (SphK), irrespective of the etiology
of fibrosis that led to liver fibrosis and cirrhosis.
SphK2 may also contribute to mast cell functions [63].
Lai, W.Q found that prior to the development of the
clinical symptoms of arthritis, depletion of SphK2 en-
hanced the production of the pro-inflammatory cyto-
kines IL-6, TNF, and IFNγ [64]. SphK2 inhibition
alleviated disorders associated with immunosuppression,
such as chronic infections and/or cancers [65]. Haber-
land, M [66] and Glauben, R [67] explained that S1P was
bound to and inhibited histone deacetylases 1 (HDAC1)
and HDAC2, which may be associated with human dis-
eases such as cancer and inflammation. Furthermore, in
Alzheimer’s disease, the activity of β-site APP-cleaving
enzyme-1 (BACE1), the rate-limiting enzyme for amyloid-
β peptide (Aβ) production, was modulated by S1P in
mouse neurons. Both SphK inhibitors and overexpression
of S1P-degrading enzymes decreased BACE1 activity,
which reduced Aβ production [68]. Cardiomyocyte ische-
mia/reperfusion (I/R) injury is fatal. S1PR1 activation and
downstream signaling through Akt enhanced ischemic
preconditioning and mammalian cardiomyocyte survival
[69]. At the same time, recent studies suggested that S1P
agonists FTY720 /SEW2871 could provide protection
against stroke and ischemic injury in many tissues [70]. In
some studies, SPL inhibitors as well as S1P analogs medi-
ated cardioprotection and prevented sepsis-related tissue
injury. High-density lipoprotein (HDL) confers protection
against atherosclerosis and heart disease. Recent studies
found that S1P mediated HDL’s circulation through
plasma carriers via its receptors [71]. S1P receptor ago-
nists or antagonists may function in vasodilation, cardio-
protection, and survival.
Unlike its positive role in cardiovascular disease, S1P
signaling also contributes to carcinogenesis [72]. SphK1
is often upregulated in cancerous tissue, and its overex-
pression correlates with chemo- and radiation-resistance
and poor prognosis [13]. SphK1 promoted cancer growth
via multiple mechanisms, including S1P signaling to can-
cer cells. Sequestering S1P with a specific S1P monoclonal
antibody blocked tumorigenesis and tumor angiogenesis
in murine xenograft and allograft cancer models [73].
Based on these observations, inhibition of SphK1 reduced
tumor growth, angiogenesis and chemoresistance in nu-
merous xenograft models [72, 74].
The role of the SphK/S1P/S1PR1 axis in cancer
Tumor cells secrete S1P, promoting growth, survival, mo-
tility, and metastasis via S1PRs in an autocrine/paracrine
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manner [75–77]. The specific processes are complex, in-
cluding endothelial adhesion, angiogenesis, and regulation
of tumor-stromal interactions [77] (see Table 1).
Interestingly, SPL and S1P phosphatase (SPP) expres-
sion were balanced in many human cancers and murine
cancer models. In knockout mouse models of human
SGPL1, which encodes SPL [78], and through quantita-
tive real-time PCR (Q-PCR) and immunohistochemical
analysis, studies found that SPL promoted apoptosis
through p53- and p38-dependent pathways. SGPL1 gene
which encodes SPL disruption in mouse embryonic
fibroblasts increased their resistance to chemotherapeu-
tic agents by upregulating Bcl-2 and Bcl-xL [79]. In
some cancers, activated SPL affected carcinogenesis to
cancer itself under stress [78]. Increasing S1P catabolism
or inhibiting S1P biosynthesis could become a new way
to treat cancer. In contrast, some studies found that the
inhibition of S1P raised secondary malignancy [13].
Targeting S1P signaling may be a double-edged sword.
Studies found that signal transducer and activator of
transcription-3 (STAT3) was important in the persistent
activation of tumors [80, 81]. STAT3 is a transcription fac-
tor for S1PR1. Enhanced S1PR1 upregulated the expression
of IL-6, a pro-inflammatory cytokine crucial for STAT3 ac-
tivation, inflammatory cell-mediated transformation, and
tumor progression [81]. The altered microenvironment is
an important factor for malignant progression and metas-
tasis [82].
Aberrant IL-6–JAK-STAT3 signaling in cancer cells is
a major mechanism for cancer initiation, development,
and progression [82–84]. Lee H used B16 cells, which
have relatively low STAT3 activity and IL-6 expression
in cell culture but greatly enhanced STAT3 activity in
vivo, achieved at least in part through IL-6 production
by the tumor stromal immune cells [85, 86]. Kujawski,
M. et al., studied the role of STAT3 in tumor-associated
MDSCs and tumor angiogenesis through C57BL/6 naive
mice [87]. Chemotactic factors, including IL-6 and IL-10,
correlated with STAT3, influencing the whole immune sys-
tem, including the formation of metastatic niches [88, 89].
Studies have found minute differences in Jak somatotypes
for STAT3, and various animal models were used to re-
veal the particular passageways in the microenviron-
ment [29, 88, 90].
Several seminal studies have documented the import-
ance of myeloid cells in providing a sanctuary for tumor
cell adhesion, survival, and secondary site colonization
[91, 92]. Myeloid cells mobilized and produced chemo-
kines and other molecules in response to the tumor envir-
onment, thereby promoting cancer progression [93, 94].
However, the role of myeloid cells in forming a sanctuary
for tumor cells in distant organs prior to tumor cell ar-
rival/outgrowth remains unknown [91, 92]. Targeting
STAT3/S1PR1 signaling in immune cells could reduce
STAT3 activity and myeloid cell infiltration in future
metastatic sites [91, 95, 96]. S1PR1-STAT3 in tumor
cells and myeloid cells orchestrated premetastatic niche
formation, and persistent STAT3 signaling in myeloid
cells could increase their proliferation and survival, as
well as that of other stromal cells at future metastatic
sites [88].
Targeting therapies toward the SphK/S1P/S1PR1
axis
In many types of cancer and in some inflammatory dis-
ease, SphK1 is overexpressed [18]. SphK1 expression, en-
zymatic activity, and subsequent S1P production were
stimulated by TNF-α, as well as by a host of other in-
flammatory signaling molecules, including IL-1β, IFN-γ,
IgE, and C5a [97]. SphK1 is accordingly a primary target
Table 1 SphK/S1P/S1PR1 axis in cancer
Which type Main cancer/bad outcomes Mechanism/causes References
Sphk1↑ Breast cancer Hemangiogenesis [76, 77, 81, 85]
Glioma Lymphangiogenesis
B17 melanoma malignance IL-17↑→ IL-6–Stat3↑→ stat3↑
MB49 bladder malignance
SphK2 ↓ Colitis-associated tumorigenesis SphK1↑ [80]
SphK1/S1P/S1PR1 axis↑
NF-κB/STAT3 ↑
S1P↑ Colon cancer S1P lyase↓→ p53-, p38-dependent pathways ↑ [78, 79]
Melanoma SGPL1 gene ↑→ S1P lyase disruption ↑→ Bcl-2, Bcl-xL dependent pathways
Resistance to chemotherapy
Stat3↑ Melanoma RelA acetylation→ NF-κB↑ [86, 87, 89]
Myeloid cell-dependent tumor BRAF–MAPK↑
A2058 tumor cells malignance VEGF/bFGF→ tube formation
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for the development of therapeutic intervention strategies
[98]. Safingol, a first-generation SphK inhibitor, had some
achievements in phase 1 clinical trials [99] (see Table 2).
SK1-I,(2R,3S,4E)-N-methyl-5-(4′-pentylphenyl)-2-ami-
nopent-4-ene-1,3-diol, designated SK1-I (BML-258),
markedly reduced the growth of AML xenograft tumors
and acute myelogenous leukemia by affecting multiple
survival signaling pathways [100]. Kapitonov found that
SK1-I reduced the growth, migration, and invasion of
several glioblastoma multiforme (GBM) cell lines by
using SphK1 inhibition. This function of SK1-I was at-
tributed to the suppression of Akt activation, and the
subsequent interruption of signaling through the Akt
pathway, which is upregulated in the majority of glio-
blastomas [99]. Meantime, a combination of SphK1 in-
hibitors and cisplatin could be used to treat patients and
provide some degree of disease regression [99].
SKI-II enhanced the resistance to apoptosis in human
non-small cell lung cancer via the PI3K/Akt/NF-κB path-
way [101]. Interestingly, SKI-II seemed to be relevant to
hormone-associated diseases. SKI-II dose-dependently de-
creased estrogen-stimulated estrogen response element
transcriptional activity and diminished the messenger RNA
(mRNA) levels of the estrogen receptor (ER)-regulated
genes progesterone receptor and steroid derived factor-1.
Therefore, blocking estrogen signaling was prospective in
targeted breast cancer therapy [102]. Another SK1 inhibi-
tor, Ski (2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole),
induced the proteasomal degradation of SK1 in human
androgen-sensitive LNCaP prostate cancer cells [103]. Fur-
ther research is needed to illustrate the specific relationship
between Ski inhibitors and hormone-mediated diseases.
Cancer studies with SphK2 are less common than those
with SphK1. Therefore, illustrating the possibility of SphK2
associated disease is difficult. In an early study, Van Brock-
lyn JR found that RNA interference of SphK2 expression
inhibited glioblastoma cell proliferation more potently than
did SphK1 knockdown [104]. One study found that in
xenograft nude mice, SphK2-deficient tumors displayed a
pronounced anti-tumor phenotype, including increased
pro-inflammatory markers NO, TNF-alpha, and IL-12
[105]. A subsequent study proposed that ABC294640, a se-
lective inhibitor of SphK1 that modulated the S1P level,
could antagonize cancers such as breast cancer and ovarian
cancer [106, 107]. The mechanism may be via the inhib-
ition of tumor cell migration, concomitant with loss of
microfilaments [98]. Correspondingly, we could develop
clinical or intervention strategies to cure or ease disease.
FTY720, an immunosuppressive small molecule drug,
bound to and eventually induced the internalization and
degradation of one out of the five known S1P cell sur-
face receptors, which prevented its function as a sensor
of S1P gradients [108]. FTY720, which is phosphorylated
in vivo by SphK2, could prevent T and B cell egress from
lymph nodes (LN) and Peyer’s patches [109], as the S1P/
S1PR axis is also important for B cell migration through
Table 2 Different drugs produce varied function in cancer
Drugs Type Main function Functional mechanism References
SK1-I Inhibitor of SphKs Leukemia Bcl-2 [77, 100,
103]
Breast cancer ERK1/2 and Akt
Prostate cancer MCF-7/MCF-7 HER2
SKI-II Inhibitor of SphKs Human non-small cell
lung cancer
PI3K/Akt/ NF-κB [101, 102]
Estrogen receptor-regulated genes
Breast cancer therapy SDF-1




ABC294640 Selective inhibitor of SphK1 Breast cancer Inhibition of tumor cell migration [98, 106,
107]
Ovarian cancer Loss of microfilaments
FTY720 Sphingosine analog Peripheral blood stem cell
(PBSC) transplantation
Internalization and degradation











Prevent T and B cell egress from
lymph nodes
S1PR1↑→ SDF-1 sensitivity↑→ CXCR4↑
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the lymph node follicle [18]. FTY720, an agonist of S1P,
has been approved for the treatment of multiple scler-
osis. Its ligands were for all of the S1PRs, except S1PR2.
The clinical efficacy of FTY720 has been attributed to its
ability to promote the retention of naive T cells and cen-
tral memory T cells (including autoreactive TH17 cells)
in lymph nodes, preventing terminally differentiated ef-
fector T cells and effector memory T cells from entering
the central nervous system and driving pathological re-
sponses. On the other hand, FTY720 minimally affected
peripheral effector memory T cells, which were important
for protection against infection [109–111].
Conclusions
Immune microenvironment is a changeable zone in
which large amounts of molecules, metabolites, and
electrochemical substances weave mixed network. The
function of sphingosine not only existed in its relation
with other sterols in chemistry but it also causes huge
biological influences through SphKs/S1P/S1PR1 axis,
including physiological/pathological processes, e.g.,
hemopoietic system, lymphocytes internalization, aller-
gic response, ischemia reperfusion injury, inflamma-
tory bowel disease, and heterogeneity of carcinoma. In
our retrospective study, many researchers illustrated
SphKs/S1P/S1PR1’s functions via “inside-out signaling”,
and some targeted drugs focused on SphKs/S1P/S1PR1
axis impact abovementioned physiological or pathological
processes (like PI3K/Akt/NF-κB pathway). Although it is
difficult to keep pace with the rapidly moving target of
S1P in the immune system, the development of a second
generation of drugs with improved specificity and efficacy
will provide new treatment strategies for these inflamma-
tory disorders and, moreover, will enhance our under-
standing of how this “simple” sphingolipid metabolite
functions both the inside and outside of cells.
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